Creative Medical Technology Holdings Inc (CELZ)

[Babubd]

Loading up and holding CELZ shares because fair value @ Dollar Land! This is grossly undervalued, a load and hold, no-brainer. Just hold your shares folks.

Shorts are screwed-up here. Over 425.18 Million Shorted volume is outstanding. Huge short squeeze is imminent. Shorts are gonna be roasted and burnt.
https://marketwirenews.com/stock/celz/short/

KNOW WHAT YOU OWN

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine(R) Personalized Adult Stem Cell Therapy

Commercial Stage Regenerative Medicine Company Expands it's Hold "Ready to Commercialize" Autologous Bone Marrow Procedures

PHOENIX, March 4, 2021 /PRNewswire/ -- (OTC - CELZ) Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease. Evaluation of patients at 30,60 90, 180, and 360 days revealed significant improvement in mobility and reduction in pain score . The mean pain changed from 8.9 at baseline to 4.3 at 30 days and sustained to 1.8 at 6 months and 1.3 at 12 months with a gradual reduction in overall pain medication utilization guided by their healthcare team. No serious adverse effects were noted with some short-term bruising in two patients at the harvest site and no long term adverse events where reported related to the procedure.

"This publication, which is "pre-peer review" describes what to our knowledge is the first demonstration of a signal of clinical efficacy by injecting stem cells in areas surrounding the disc." Said Dr Amit Patel, Board Member and Co-Founder of the Company. "While others have intra-disc injection may help disc pain, the current work regenerates the blood supple to the disc, allowing the disc to heal itself."

The autologous utilization of bone marrow falls under the "minimal manipulation exception" and can be commercialized rapidly, in the same manner that the Company commercialized Caverstem(R) for treatment of erectile dysfunction.

Granted United States Patent #9,598,673 which is owned by the Company covers the use of any mesenchymal stem cells, both from the patient or from donors, for reduction of lower back pain when injected into the major muscles of the lower back.

"Disc degenerative disease represents a multi-billion dollar market for which current medical solutions do not address the underlying cause, while surgery is expensive and not applicable for a significant number of patients." Said Timothy Warbington, President and CEO of the Company. "We are excited to follow the path we did with CaverStem(R) and initiate commercialization of this technology for American patients."

To view our Publication: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3797402

Creative Medical Technology Holdings Provides Update on ImmCelz(R) FDA Application

PHOENIX, March 3, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings announced today that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz(R) Investigational New Drug Application (IND) for the treatment of Stroke will be resubmitted to the FDA in electronic form to comply with such requirements. Previously, the FDA had accepted IND applications in hard copy submitted by mail.

Due to the complexity of the new requirements, Creative Medical Technology Holdings has retained the services of an FDA consulting firm with the expertise to assist it with the FDA's electronic submission procedures, which include formatting, hyperlinking, and tagging requirements. The Company believes that retaining a third party firm experienced in FDA electronic submissions will better equip the Company to navigate and comply with the FDA's new requirements.

Resubmission of the Company's ImmCelz(R) IND will not change the substance of the Company's application to the FDA. As previously reported, the IND seeks approval from the FDA to initiate the first clinical trial using cellular immunotherapy for treatment of stroke, using the Company's ImmCelz(R) product.

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz(R), February 16, 2021

Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation

***Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem(R) Female Infertility/Ovarian Failure Treatment

PHOENIX, Feb. 10, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem(R) female infertility/ovarian failure treatment. OvaStem(R), which is covered by issued patent #10,792,310, involves injection of stem cells into dysfunctional ovaries and has been demonstrated to induce fertility, as well as restore hormone levels.

The data, which are covered in a newly filed patent application, demonstrate that mesenchymal stem cell injection results in generation of T regulatory cells. These cells are a type of immune cell which the Company has previously patented for regeneration of lumbar discs (US Patent #10,842,815). Importantly, depletion of T regulatory cells resulted in negation of the beneficial effects of stem cells, whereas exogenous administration of T regulatory cells are capable of restoring ovarian function.

"Cellular therapy is making significant advances in the treatment of cancer, degenerative diseases, and autoimmunity." Said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "We are pleased to discover this interesting interaction between mesenchymal stem cells and T regulatory cells in prevention of ovarian failure and restoration of function. By elucidating mechanisms, we feel we are making progress towards eventual filing with the FDA for initiation of clinical trials."

Although the menopause market is believed to be approximately $600 billion[1], the Company is focusing on the initial indication of premature ovarian failure. Premature ovarian failure occurs in woman under 40 who experience degeneration of ovaries from a variety of conditions. The Company has demonstrated efficacy of autologous (patient's own stem cells) and allogeneic (universal donor) in animal models of this condition.

"Despite having a wide variety of cellular products in development, there appears to be a common theme of interaction between mesenchymal stem cells and T regulatory cells." Said Timothy Warbington, President and CEO of the Company. "Today's discovery that T regulatory cells are effective in treatment of ovarian failure lends more scientific support to OvaStem(R), which we hope will accelerate our path towards FDA clinical trials to treat this condition."

***Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board

Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz(R) Regenerative Immunotherapy

PHOENIX, Feb. 8, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British Columbia to the Company's Scientific Advisory Board.

Dr. Du is a top researcher in the area of molecular and immunological understanding of kidney failure and transplant rejection. Dr. Du is funded by numerous national and international organizations including the Kidney Foundation and the Canadian Institutes of Health Research.

"I am honored to work with Creative Medical Technology Holdings in this fascinating field of leveraging reprogrammed immune cells for regenerating injured kidneys." Said Dr. Du. "To date people think about regenerative medicine and immunology as separate fields. It is very exciting to consider the possibility that immune cells can act as a catalyst for regenerative processes: this is the basis of the ImmCelz(R) product."

ImmCelz(R) is a personalized cell therapy generated by incubation of patient cells with allogeneic JadiCell stem cells under proprietary conditions. The JadiCell possess potent ability to reprogram the immune system, as exemplified in part by their ability to significantly extend survival of COVID patients in an FDA double blind, placebo controlled, clinical trial(1) . ImmCelz(R) has been demonstrated effective in animal models of rheumatoid arthritis(2) , liver failure(3) , stroke(4) , type 1 diabetes(5) and kidney failure(6) . Scientific studies suggest ImmCelz(R) functions through secretion of a fundamentally important molecule called Hepatocyte Growth Factor(7) , as well as stimulation of T regulatory cells, a type of immune system cell that suppresses pathological immunity(8) .

"As a clinical-stage biotechnology company, having already commercialized other stem cell products, we understand the key to any success is based on the ability to attract scientific key opinion leaders." Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "Dr. Du is a visionary and pioneer in understanding of kidney diseases and we wholeheartedly look forward to him joining our scientific advisory board."

The Advisory Board of Creative Medical Technology Holdings includes internationally renowned neurologist Santosh Kesari MD, Ph.D, the former head of cardiology at Cedar Sinai Medical Center Timothy Henry, MD and our Director Dr. Amit Patel, inventor of the JadiCell and the first physician to have implanted stem cells into the human heart.

***Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz(R) Therapeutic Activity, Monday, February 1, 2021

Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz(R) Induces Surge of Therapeutic Protein HGF-1

PHOENIX, Feb. 1, 2021 /PRNewswire/ -- (OTC -- CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz(R) to animals with a variety of conditions results is a significant surge of the protein hepatocyte growth factor (HGF-1). When scientists blocked the effects of HGF in ImmCelz(R) treated animals, the therapeutic effects where significantly inhibited. The data suggests one of the molecular mechanisms of action of ImmCelz(R) is mediated by production of this therapeutic molecule.

"One of the drawbacks of many cellular therapies is their complicated, and many times ill-defined mechanisms of action." Said Dr. Amit Patel, co-founder of the company and co-inventor of the patent application. "I am proud of our scientific team for focusing not only on the exploration of therapeutic benefits of ImmCelz(R) in a wide variety of diseases, but also on homing in on mechanisms of action. We have previously reported ImmCelz(R) induces T regulatory cells and endogenous neurogenesis.(1) The current data suggests that HGF-1 may be acting upstream of these effects."

To date the Company has reported therapeutic activity of ImmCelz(R) in models of rheumatoid arthritis,(2) stroke,(3) type 1 diabetes,(4) kidney failure(5) and liver failure.(6) The data disclosed today are supported by independent studies which have shown HGF-1 is capable of inducing T regulatory cells(7,8) and stimulating neurogenesis.(9,10)

"Cellular immunotherapy has commanded extremely lucrative valuations for companies in early stages of clinical trials." Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "We believe for regenerative immunotherapy products such as ImmCelz(R) to attract similar valuations, understanding of biological mechanisms of action is important. I commend our scientific collaborators for their work that resulted in this current patent filing."

***Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz(R) Regenerative Immunotherapy
Wednesday, January 27, 2021, 7:45 AM ET

Clinical Stage Cellular Therapy Company Advances Product Pipeline into Kidney Failure Market!!

PHOENIX, Jan. 27, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz(R) Regenerative Immunotherapy product reduced/reversed kidney failure in an animal model. Using the classical "ischemia/reperfusion" system, collaborators of the Company demonstrated significant reduction in markers of kidney injury at multiple timepoints after kidneys were clamped to replicate renal injury.

"Kidney failure is a significant cause of suffering today. One particular area of kidney damage that is of great interest is preventing injury associated with cardiovascular bypass. One report states that as many as 30% of patients undergoing bypass have some level of renal damage(1) ." Said Dr. Amit Patel, co-inventor of the patent and Board Member of the Company. "The preliminary animal data suggests that ImmCelz(R) may have superior activity to conventional stem cell based approaches. This may be due to the smaller size of immune cells that comprise the ImmCelz(R) product, as well as due to factors we are still investigating."

According to a BCC Research Report, entitled "Chronic Kidney Disease: Global Markets and Technologies Through 2023" the global market for chronic kidney disease is anticipated to grow from $79.0 billion in 2018 to reach $95.0 billion by 2023 at a compound annual growth rate (CAGR) of 3.8% for the period of 2018-2023(2) .

"It is important to note that the JadiCell, which has been demonstrated by a double-blind placebo controlled clinical trial to be effective against COVID-19 lung failure(3) , is the "engine" behind ImmCelz(R) said Timothy Warbington, President and CEO of the Company. "The demonstration that this cell type, which already has cleared FDA trials, can bestow regenerative properties to blood cells is, in our minds, paradigm shifting. We are excited to include this technology in our robust intellectual property portfolio and eager to file our Investigational New Drug application (IND) with the FDA to begin clinical trials."

The JadiCell clinical trial consisted of 24 patients randomized 1:1 to either JadiCell (UC-MSC) treatment (n = 12) or the control group (n = 12). According to the publication, treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS(4) .

***Creative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz(R) Through FDA, Thursday, January 21, 2021

***Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz(R) Regenerative Immunotherapy!!

***CELZ Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using "Reprogrammed" Immune Cells - Wow!!

Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz(R) Personalized Cellular Immunotherapy in Preclinical Model